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We reported previously that ;80-kilobase pair (kb) P1
bacteriophage clones spanning either the human or
mouse apoB gene (clones p158 and p649, respectively)
confer apoB expression in the liver of transgenic mice,
but not in the intestine. We hypothesized that the ab-
sence of intestinal expression was due to the fact that
these clones lacked a distant DNA element controlling
intestinal expression. To test this possibility, transgenic
mice were generated with 145- and 207-kb bacterial ar-
tificial chromosomes (BACs) that contained the human
apoB gene and more extensive 5*- and 3*-flanking se-
quences. RNase protection, in situ hybridization, immu-
nohistochemical, and genetic complementation studies
revealed that the BAC transgenic mice manifested ap-
propriate apoB gene expression in both the intestine
and the liver, indicating that both BACs contained the
distant intestinal element. To determine whether the
regulatory element was located 5* or 3* to the apoB gene,
transgenic mice were generated by co-microinjecting
embryos with p158 and either the 5*- or 3*-sequences
from the 145-kb BAC. Analysis of these mice indicated
that the apoB gene’s intestinal element is located 5* to
the structural gene. Cumulatively, the transgenic mouse
studies suggest that the intestinal element is located
between 233 and 270 kb 5* to the apoB gene.
The B apolipoproteins apoB48 and apoB100 play central
roles in lipoprotein metabolism and are components of all li-
poproteins considered to be atherogenic (1, 2). ApoB48 synthe-
sis in intestinal enterocytes is required for the assembly of
chylomicrons (1, 3), whereas apoB100 synthesis in liver hepa-
tocytes is required for the generation of very low density li-
poproteins (1). Of note, the basic role of apoB, to serve as the
structural protein in the assembly of triglyceride-rich lipopro-
teins, is essentially the same in both the liver and the intestine.
Even though apoB plays the same functional role in hepato-
cytes and intestinal enterocytes and even though both cell
types arise from primitive gut tissue during embryonic devel-
opment (4), there is strong evidence to suggest that the genetic
control of apoB gene expression in the liver is distinct from that
in the intestine. To assess the effect of apoB overexpression on
lipid metabolism, we generated human apoB transgenic mice
with an 80-kb1 P1 bacteriophage clone (p158) that spans the
entire human apoB gene and contains 19 kb of 59-flanking
sequences and 17.5 kb of 39-flanking sequences (5). Remark-
ably, the human apoB transgene was expressed at high levels
in the liver, but not at all in the intestine. This pattern of
expression was observed in many transgenic lines in our labo-
ratory and was also documented in independent studies by
another laboratory (6). Moreover, in human apoB transgenic
rabbits that we generated with p158, transgene expression was
high in the liver, but undetectable in the intestine (7). This
absence of intestinal expression with the large p158 transgene
was unexpected because transient transfection assays in intes-
tinal or liver cell lines using apoB promoter-reporter gene
constructs had suggested that as few as 260 bp of the apoB gene
promoter were sufficient for apoB expression in the intestine
and the liver (8). Moreover, we found the transgenic mouse
expression data intriguing simply because the absence of in-
testinal transgene expression contrasted so sharply with the
normal hepatic expression pattern. While transgene expression
in the intestine was undetectable even by the most sensitive
techniques (i.e. reverse transcription-polymerase chain reac-
tion) (9), expression in the liver was robust and completely
homogeneous (not variegated) and appeared to be copy number-
dependent and position-independent (5, 6), all indications that
this large clone contained all of the sequences required for
appropriate gene expression.
More recently, we excluded the possibility that the absence of
human apoB expression in the intestine resulted from our
attempt to express a human transgene in another species. A P1
clone spanning the mouse apoB gene (including 33 kb of 59-
flanking sequences and 11 kb of 39-flanking sequences) yielded
high levels of expression in transgenic mouse liver, but abso-
lutely none in the intestine, as judged by a sensitive transgene-
specific RNase protection assay (10). In the latter study, the
absence of intestinal transgene expression was underscored by
mating the transgenic mice with apoB knockout mice. Mouse
apoB transgenic mice that were homozygous for a knockout
mutation in the endogenous apoB gene expressed the apoB
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transgene in the liver, but lacked all apoB synthesis in the
intestine, leading to a massive accumulation of fat within in-
testinal enterocytes (10). The results of these experiments,
together with the earlier transgenic experiments with p158,
suggested that distant DNA sequences, perhaps located .33 kb
59 or .17.5 kb 39 to the gene, might be required for the expres-
sion of apoB in the intestine. In this study, we sought to test the
hypothesis that appropriate expression of apoB in the intestine
is controlled by a distant regulatory element.
MATERIALS AND METHODS
BAC and P1 Bacteriophage Clones—Two BAC clones spanning the
human apoB gene were identified by polymerase chain reaction screen-
ing of libraries of human genomic DNA (5, 11). A 207-kb clone, desig-
nated BAC(120,35) because it had 120 kb of 59-flanking sequences and
35 kb of 39-flanking sequences, was identified in a library constructed in
pBAC108L; a 145-kb clone, designated BAC(70,22) because it had 70 kb
of 59-flanking sequences and 22 kb of 39-flanking sequences, was iden-
tified in a library constructed in pBeloBAC11. The BAC clones were
mapped by a combination of restriction endonuclease digestion, pulsed-
field gel electrophoresis, Southern blot analysis, and automated DNA
sequencing (10, 12, 13). Two NotI fragments of BAC(70,22) (a 70-kb
fragment spanning from the 59-polylinker NotI fragment in the BAC to
the NotI site within intron 1 of the apoB gene and a 66-kb fragment
spanning from the NotI site within intron 1 to the 39-polylinker NotI
site in the BAC) were purified from NotI-cleaved BAC(70,22) DNA and
ligated into a NotI-cleaved and dephosphorylated P1 bacteriophage
vector to generate two new P1 clones, P1–70 and P1–66 (see Fig. 1).
Preparation of DNA for Microinjection and Generation of Transgenic
Mice—To prepare DNA for microinjection, BAC DNA was cleaved with
NruI or BssHII (see Fig. 1), and P1 bacteriophage DNA was cleaved
with NruI or MluI. These enzymes cleave the vectors twice, but do not
cleave the insert. The cleaved DNA was size-fractionated on a 1% low
melting point pulsed-field agarose gel (Seaplaque GTG, FMC Corp.
BioProducts, Rockland, ME). The segment of the gel containing the
large DNA fragment was excised and digested with gelase (Epicentre
Technologies Corp., Madison, WI) (14). The DNA solutions were ad-
justed to 3 ng/ml and used to microinject fertilized mouse eggs (C57BL/
6J 3 SJL); co-injected fragments were 3 ng/ml each.
To identify transgenic mice, mouse plasma samples were screened
with a radioimmunoassay specific for human apoB (5). Transgenic lines
were established by mating founder animals with C57BL/6J mice. To
generate transgenic mice lacking expression of the endogenous mouse
apoB gene, BAC(70,22) transgenic mice were bred with heterozygous
apoB knockout mice (apoB1/2) (15). Transgenic mice that lacked mouse
apoB expression (BAC(70,22)apoB2/2) were identified by Southern blot
analysis of tail DNA and by Western blot analysis of mouse plasma. Slot
blot analysis with a 32P-labeled 1857-bp BamHI-EcoRI fragment from
exon 26 of the human apoB gene (corresponding to apoB cDNA nucle-
otides 4650–6507) was used to assess transgene copy number.
To evaluate whether the ends of the BAC transgenes had integrated
into the genome of transgenic mice, a 272-bp fragment of the BAC
vector at the 59-end of the linearized transgene was amplified by po-
lymerase chain reaction with oligonucleotides 59-GTATTCAGT-
GTCGCTGATTTG-39 and 59-CATTTAGTTATGACGAAGAAG-39. In
parallel, a 322-bp fragment of the BAC vector at the 39-end of the
transgene was amplified with oligonucleotides 59-GTAATATCCAGCT-
GAACGGTCTG-39 and 59-CTGTGACGGAAGATCACTTCGCAG-39.
Finding both ends of the BAC vector in genomic DNA provided sugges-
tive (but not definitive) evidence that the BAC transgene was intact
within the chromosomal DNA.
Plasma Lipoprotein Analysis—Human apoB and mouse apoB in
mouse plasma were detected by Western blot analysis of SDS-polyacryl-
amide gels (16). To detect human apoB, we used an antiserum to human
apoB that had been absorbed against mouse apoB by passing it over a
mouse apoB-Sepharose 4B column. To prepare the column, apoB-con-
taining mouse lipoproteins (d , 1.040 g/ml) were coupled to CNBr-
activated Sepharose 4B (Pharmacia Biotech Inc.) according to the man-
ufacturer’s instructions. An antiserum specific for mouse apoB was
prepared by immunizing a human apoB transgenic rabbit (7) with
purified mouse apoB (17).
RNase Protection Assays—Total cellular RNA was isolated from
mouse tissues with the Totally RNA kit (Ambion Inc., Austin, TX). T7
RNA polymerase was used to prepare antisense mRNA transcripts from
linearized plasmids. One human apoB probe spanned the first 121
nucleotides of exon 1 of the apoB gene; another probe was a 220-bp
fragment of exon 26 (human apoB cDNA nucleotides 4487–6507). The
mouse apoB probe was a 245-bp XbaI-MscI fragment of exon 26 of the
mouse apoB gene (17). A 316-bp mouse GAPDH probe was purchased
from Ambion Inc. The RNase protection experiments were performed
with the RPA II ribonuclease kit from Ambion Inc.; electrophoresis was
performed on a 6% polyacrylamide gel containing 8.3 M urea (Boeh-
ringer Mannheim). Protected RNA fragments were visualized by auto-
radiography or with a PhosphorImager.
Immunocytochemistry—Mouse tissues were fixed in 4% paraformal-
dehyde and embedded in paraffin. Sections (4 mm thick) were mounted
on glass slides. After deparaffinization in xylene, the sections were
rehydrated; embedded in 10 mM citrate buffer, pH 6.0;, and boiled in a
microwave oven for 3 min. The slides were incubated with phosphate-
buffered saline, pH 7.4 (Sigma), with 0.5% casein and 0.1% Tween 20 for
30 min, followed by incubations first with an antiserum to mouse apoB
(1:250), an antiserum to human apoB (1:250), or preimmune rabbit
serum (undiluted); then with biotinylated goat anti-rabbit antibody
(1:200; Vector Laboratories, Inc., Burlingame, CA); and finally with
streptavidin-alkaline phosphatase (BioGenex Labs, San Ramon, CA).
Finally, the slides were incubated with Vector Red (Vector Laborato-
ries, Inc.) for 15 min and counterstained with hematoxylin.
In Situ Hybridization—Plasmid pBSSKsmaK/X (18) was linearized
with XbaI and KpnI, respectively, and human apoB 35S-riboprobes were
synthesized with T7 (antisense probe) and T3 (sense probe) RNA po-
lymerases (Promega, Madison, WI). To prepare the 245-bp mouse apoB
35S-riboprobes, plasmid pBSmB245 (17) was linearized with XbaI and
XhoI, respectively, and 35S-riboprobes were synthesized with T7 (anti-
sense probe) and T3 (sense probe) RNA polymerases.
In situ hybridizations of the 35S-riboprobes were performed as de-
scribed (19). Briefly, tissue sections were deparaffinized in xylene,
followed by hydration and a 10-min fixation in 4% paraformaldehyde.
After treatment with proteinase K (1 mg/ml in 500 mM NaCl and 10 mM
Tris-HCl, pH 8.0) for 10 min, followed by a 10-min wash in 0.5 3 SSC,
tissue sections were prehybridized at 55 °C for 1–3 h in a buffer con-
taining 50% formamide, 0.3 M NaCl, 20 mM Tris, pH 8.0, 5 mM EDTA,
1 3 Denhardt’s solution (Sigma), 10% dextran sulfate (Sigma), and 20
mM dithiothreitol. 35S-Riboprobe and tRNA (300,000 cpm and 20 mg/100
ml of the prehybridization buffer, respectively) were then added and
incubated at 55 °C for 14–18 h. Unbound 35S-riboprobe was removed by
washes with 2 3 SSC containing 10 mM b-mercaptoethanol and 1 mM
EDTA, followed by RNase A (Sigma) treatment. The slides were then
further washed two times in 2 3 and 0.1 3 SSC, respectively. For
autoradiography, the slides were dipped in Eastman Kodak NTB2
nuclear emulsion (diluted 1:1 with H2O and prewarmed at 42 °C),
air-dried for 2 h, and exposed for 4–8 weeks at 4 °C. The slides were
developed at 15 °C using reagents from Kodak and stained with hema-
toxylin and eosin.
RESULTS
A 207-kb BAC that spanned the coding regions of the human
apoB gene and contained 120 kb of 59-flanking sequences and
35 kb of 39-flanking sequences (BAC(120,35)) (Fig. 1) was used
to generate human apoB transgenic mice. In one transgenic
line, BAC vector sequences on both the far 59- and 39-ends of the
transgene could be amplified from transgenic mouse tail DNA
(Fig. 2). To investigate whether sequences within BAC(120,35)
conferred intestinal expression of the apoB gene, RNA was
prepared from the liver and duodenum of F1 transgenic mice
and analyzed by RNase protection assays. In contrast to trans-
genic mice generated with the ;80-kb P1 bacteriophage clone
(p158), which manifested transgene expression only in the
liver, the BAC(120,35) transgenic mice expressed human apoB
in both the liver and the duodenum (Fig. 3).
To localize further the DNA sequences that direct intestinal
expression of apoB, we isolated a BAC that contained 70 kb of
59-flanking sequences and 22 kb of 39-flanking sequences
(BAC(70,22)) (Fig. 1) and used it to generate additional lines of
human apoB transgenic mice. A high-expressing line, with ;13
copies of the human apoB transgene integrated into the mouse
genome, was chosen for extensive analysis. Both ends of the
BAC(70,22) transgene could be amplified from mouse genomic
DNA (Fig. 2). Moreover, Southern blot analysis of mouse
genomic DNA that had been digested with NotI and size-frac-
tionated on a pulsed-field agarose gel also indicated that the
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BAC(70,22) transgene was intact.2 On a chow diet, this trans-
genic line had human apoB levels of ;60 mg/dl and high levels
of low density lipoprotein cholesterol, as judged by fast-phase
liquid chromatography analysis (Fig. 4). Furthermore, trans-
gene expression in the liver hepatocytes was uniform, as judged
by both in situ hybridization and immunohistochemistry (data
not shown), indicating that the BAC(70,22) transgene directed
fully appropriate apoB expression in the liver without trans-
gene variegation.
RNase protection analysis of intestinal and liver RNAs from
BAC(70,22) transgenic mice revealed abundant amounts of
human apoB mRNA in both tissues (Fig. 3). To assess whether
the BAC(70,22) transgene directed a spatially appropriate pat-
tern of apoB gene expression in the intestine, the stomach-to-
colon and the crypt-to-villus expression patterns of both the
mouse and human apoB genes were examined. RNase protec-
tion assays demonstrated that the human apoB transgene was
expressed at high levels in the duodenum and the jejunum and
at lower levels in the ileum; transgene expression was not
detectable in the colon or the stomach (Fig. 5A). This expres-
sion pattern was identical to that of the endogenous mouse
apoB gene (Fig. 5B). As judged by a quantitative analysis of
RNase protection assays with a PhosphorImager, the amounts
of human apoB mRNA in the duodenum and the jejunum were
55 and 61% of that in the liver, respectively, whereas the
corresponding amounts of endogenous mouse apoB mRNA in
the duodenum and the jejunum were 56 and 51% of that in the
liver, respectively.
The appropriateness of the BAC(70,22) transgene expression
along the crypt-to-villus axis in the intestine was evaluated by
analyzing the expression of both the human apoB transgene
2 NotI cleaves BAC(70,22) in the vector sequences at the far 39- and
59-ends of the transgene and within intron 1 of the apoB gene, gener-
ating a 70-kb 59-fragment and a 66-kb 39-fragment (Fig. 1). In Southern
blot experiments, we used a 32P-labeled 1.1-kb HindIII-StuI fragment
from the apoB gene promoter region (i.e. 59 to the intron 1 NotI site) (48)
and a 32P-labeled 2.7-kb HindIII fragment from exon 26 of the human
apoB gene (i.e. 39 to the intron 1 NotI site) (5) to confirm the presence of
the two NotI fragments in genomic DNA of BAC(70,22) transgenic mice
(data not shown).
FIG. 1. Map of two BAC clones spanning the human apoB gene. BAC clones were mapped by a combination of restriction endonuclease
digestion, pulsed-field gel electrophoresis, Southern blot analysis, and direct DNA sequencing.
FIG. 2. Assessment of the intactness of BAC transgenes within
the genomic DNA of a transgenic mouse. A 272-bp fragment at the
59-end of the transgene and a 322-bp fragment at the 39-end of the
transgene were amplified from genomic DNA of BAC(70,22) and
BAC(120,35) transgenic mice with BAC vector-specific primers. Ampli-
fication of these sequences from BAC(70,22) plasmid DNA was used as
a positive control.
FIG. 3. RNase protection assay illustrating human apoB ex-
pression in the liver and duodenum of BAC(120,35) and
BAC(70,22) transgenic mice. The RNase protection assay was per-
formed with a 121-bp human apoB riboprobe and revealed that both of
the BAC transgenes conferred expression in the liver (5 mg of RNA) and
the intestine (5 mg of RNA), whereas the 80-kb P1 clone (p158) yielded
expression only in the liver.
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and the endogenous mouse apoB gene by in situ hybridization.
Both the human and mouse apoB genes were expressed in
enterocytes of the intestinal villi, but not in the crypts (Fig. 6).
To determine whether the absolute level of human apoB protein
expression in the BAC(70,22) transgenic mice was physiologically
appropriate, we mated those mice with heterozygous apoB knock-
out mice and ultimately generated transgenic mice lacking mouse
apoB gene expression (BAC(70,22)apoB2/2). The absence of mouse
apoB expression was established by Western blot analysis of mouse
plasma with antibodies specific for human or mouse apoB (Fig. 7).
In control experiments, we generated p158apoB2/2 mice, which
lacked all apoB expression (mouse or human) in the intestine. The
p158apoB2/2 mice had growth retardation and manifested a mas-
sive accumulation of fat within the villus enterocytes (Fig. 8). In
contrast to the p158apoB2/2 mice, the BAC(70,22)apoB2/2 mice
grew normally, and microscopic analysis of the intestines showed
normal histology and no evidence of intestinal fat accumulation
(Fig. 8). As expected from the results of the in situ hybridization
analysis, immunohistochemical staining of intestinal sections of
the BAC(70,22)apoB2/2 mice revealed expression of human apoB
in the villus enterocytes. Mouse apoB expression was undetectable
(Fig. 9).
The fact that BAC(70,22) contained both more extensive 59-
and 39-sequences than p158 meant that we could not draw
conclusions regarding whether the intestinal element was lo-
cated upstream or downstream from the structural gene. To
address this issue, we subcloned the two NotI fragments from
BAC(70,22) (Figs. 1 and 10A) into a P1 bacteriophage vector.
P1–70 contained 70 kb of 59-flanking sequences; P1–66 con-
tained 22 kb of 39-flanking sequences. Additional lines of trans-
genic mice were generated by co-microinjecting fertilized
mouse eggs with p158 and either P1–70 or P1–66. Transgenic
lines generated by co-microinjecting p158 with P1–70 ex-
pressed the human apoB gene at high levels in both the liver
and the intestine (Fig. 10B). Southern blot analysis indicated
that both DNA fragments had integrated into the mouse ge-
nome (Fig. 10C). In contrast to these results, human apoB
transgenic mice generated by co-microinjecting p158 and
P1–66 lacked apoB gene expression in the intestine (Fig. 11).
DISCUSSION
Soon after the apoB cDNA and gene were cloned (20–22), the
function of the proximal promoter sequences of the apoB gene
FIG. 4. Distribution of cholesterol in the plasma of BAC(70,22)
transgenic mice. Plasma samples (200 ml) from a BAC(70,22) trans-
genic mouse and a nontransgenic mouse were subjected to fast-phase
liquid chromatography on a Superose B6 10/50 column (Pharmacia
Biotech Inc.) (5). The cholesterol content in plasma fractions was deter-
mined enzymatically (cholesterol high performance diagnostic system,
Abbott). VLDL, very low density lipoprotein; LDL, low density lipopro-
tein; HDL, high density lipoprotein.
FIG. 5. Expression of the human and mouse apoB genes along
the stomach-to-colon axis. A, RNA (10 mg), prepared from liver and
intestinal sections of a BAC(70,22) mouse, was used in an RNase
protection assay with a 220-bp human apoB riboprobe and a 316-bp
mouse GAPDH riboprobe. B, RNA (10 mg), prepared from liver and
intestinal sections of a nontransgenic mouse, was used in an RNase
protection assay with a 245-bp mouse apoB riboprobe and a 316-bp
mouse GAPDH riboprobe.
FIG. 6. Crypt-to-villus expression patterns of the BAC(70,22)
human apoB transgene and the endogenous mouse apoB gene. A
and B, in situ hybridizations of human apoB antisense and sense
riboprobes, respectively, onto duodenal sections from a BAC(70,22)
transgenic mouse; C, in situ hybridization of a human apoB antisense
riboprobe onto a duodenal section from a nontransgenic mouse; D and
E, in situ hybridizations of mouse apoB antisense and sense riboprobes,
respectively, onto duodenal sections from a BAC(70,22) transgenic
mouse.
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was evaluated by transient transfection of reporter gene con-
structs into liver and intestinal cell lines (HepG2 and CaCo2
cells) (8, 23). The results of these experiments suggested that
260 bp of upstream sequences were sufficient to direct the
expression of the apoB gene in both the liver and the intestine.
The conclusion that proximal promoter sequences might con-
trol expression in both tissues seemed plausible. The physio-
logic role of apoB is essentially the same in both tissues, and
there are convincing precedents that proximal promoter se-
quences are sufficient to direct both liver and intestinal gene
FIG. 7. Western blot of the plasma from a BAC(70,22) trans-
genic mouse that was homozygous for a knockout mutation in
the mouse apoB gene (BAC(70,22)apoB2/2) using mouse and hu-
man apoB-specific antibodies.
FIG. 8. Oil red O-stained duodenal sections from human apoB
transgenic mice that were homozygous for a knockout mutation
in the mouse apoB gene.
FIG. 9. ApoB expression in the intestines of mice that express
human apoB, but not mouse apoB. Immunohistochemical staining
is shown of apoB in sections of duodenum from a BAC(70,22) transgenic
mouse that was homozygous for a knockout mutation in the endogenous
apoB gene (B and D) or from a nontransgenic mouse (A and C). Sections
were stained with a rabbit antiserum to mouse apoB (A and B) or with
a rabbit antiserum to human apoB (C and D).
FIG. 10. DNA sequences 5* to the apoB gene direct intestinal
expression in transgenic mice. A, ethidium bromide-stained pulsed-
field agarose gel of NotI-cleaved BAC(70,22), P1–70, and P1–66 DNAs;
B, RNase protection assay with a 121-bp human apoB riboprobe dem-
onstrating expression of human apoB in the liver (5 mg of RNA) and the
intestine (25 mg of RNA) in two transgenic mouse lines (1792 and 1798)
generated by co-microinjection of p158 and P1–70; C, Southern blot
analysis of EcoRI-digested transgenic mouse tail DNA and BAC(70,22)
plasmid DNA. Transgenic lines 1792 and 1798 were generated by
co-microinjecting fertilized mouse eggs with p158 and P1–70. The
Southern blot was probed with either a 32P-labeled 1857-bp BamHI-
EcoRI fragment from exon 26 of the human apoB gene or with a
32P-labeled ;4-kb EcoRI fragment located ;58 kb 59 to the human apoB
gene. The exon 26 probe hybridizes selectively to p158, whereas the
P1–70 probe hybridizes selectively to P1–70. Both probes hybridize to
BAC(70,22) plasmid DNA.
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expression.3 More recently, however, transgenic mouse expres-
sion studies with P1 bacteriophage clones have strongly sug-
gested the possibility of a very different scenario for apoB: that
the DNA sequence elements governing apoB gene expression in
the intestine and the liver might be entirely distinct, with
intestinal expression requiring a distant enhancer element,
perhaps located .33 kb from the transcription initiation site of
the apoB gene (3, 5, 6, 9, 17, 24, 25). In this study, we put that
hypothesis to the test by generating human apoB transgenic
mice from BACs containing more extensive 59- and 39-flanking
sequences. The initial set of experiments demonstrated that a
207-kb BAC directed apoB expression in both the liver and the
intestine, and subsequent experiments revealed that a much
smaller (145-kb) BAC was sufficient for intestinal apoB gene
expression.
To further localize the DNA sequences that direct intestinal
expression of apoB, we co-microinjected p158 (which alone does
not confer intestinal apoB expression) with DNA fragments
containing either the 59- or 39-portion of BAC(70,22). When two
DNA fragments are co-microinjected into mouse embryos, they
typically integrate into the same site within the genome and
co-segregate in subsequent breeding experiments (26). We
chose the co-microinjection strategy because it had been used
previously to examine a distant enhancer element for the im-
munoglobulin l gene; co-microinjection of a cosmid containing
the immunoglobulin l gene coding region and a cosmid harbor-
ing a distant 39-enhancer element yielded high-level, tissue-
specific expression of the l transgene in B lymphocytes of
transgenic mice (27). In our studies, we found that transgenic
mice generated by co-microinjection of p158 and P1–70 (con-
taining 70 kb of 59-flanking sequences) manifested robust hu-
man apoB expression in the intestine. When considered in
combination with our previous P1 bacteriophage experiments,
the current studies indicate that intestinal expression of the
apoB gene requires a distant DNA sequence element located
between 33 and 70 kb 59 to the apoB gene (Fig. 12).
Gordon and co-workers (28–33) have provided important
documentation that gene expression patterns in the intestine
are regulated genetically on multiple levels: temporally during
development and spatially along both the cephalocaudal axis
and the crypt-to-villus axis. Moreover, the DNA sequences
responsible for different spatial patterns of gene expression in
the intestine can be entirely distinct and can involve both
positive and negative elements. For example, Simon et al. (28),
using reporter gene expression studies in transgenic mice,
identified seven distinguishable cis-acting elements within the
;4 kb of sequences upstream from the Fabpl-coding sequences
that affected the spatial pattern of Fabpl gene expression in the
intestine. Remarkably, a reporter gene construct containing
the entire 4 kb of upstream sequences directed inappropriate
expression of the transgene in enterocytes of the colon, imply-
ing that additional sequence elements are important for the
correct pattern of Fabpl gene expression. Also, transgenic
mouse experiments with apoA-I genomic clones have demon-
strated that an intestinal enhancer element, located ;9 kb
downstream from the apoA-I gene (34, 35), is required for
intestinal expression of the apoA-I gene. Unexpectedly, how-
ever, this enhancer element yielded transgene expression in
the crypt cells and in neuroendocrine cells (sites where the
apoA-I gene is normally silent) (34), implying that other, as yet
unidentified regulatory elements were necessary for a fully
appropriate pattern of apoA-I gene expression. In light of these
studies, we considered it essential to determine whether the
BAC clones contained sufficient sequences to yield appropriate
patterns of apoB gene expression in the intestine. Our analysis
of the BAC(70,22) mice in this study revealed that the intesti-
nal expression pattern of the transgene was identical to that of
the endogenous apoB gene, with high levels of expression in the
villus enterocytes of the duodenum and the jejunum and no
expression in the colon or the crypt cells. Moreover, the BAC
clones yielded physiologically appropriate apoB expression, as
judged by the fact that the transgenic mice lacking synthesis of
endogenous mouse apoB grew normally and had no fat accu-
mulation in intestinal enterocytes.
While this study provides definitive evidence that a distant
element controls intestinal expression of the apoB gene, it
offers no insight into why the intestinal regulatory sequences of
apoB are located so far from the coding sequences or how this
complex pattern of regulation evolved. There are, of course,
precedents for control of gene expression by distant cis-acting
regulatory elements (27, 35–42). The best characterized exam-
ple is within the b-globin locus, where a locus control region
located 6–22 kb 59 to the human e-globin gene controls the
temporal and spatial expression of the b-globin family of genes
(39, 43–47). Tissue-specific expression of growth hormone in
the pituitary is controlled by interacting DNA sequences 15
and 30 kb 59 to the five-member growth hormone gene cluster
(37). A locus control region located 15 kb downstream from the
apoE gene controls the hepatic expression of several genes in
the apoE/apoC-I/apoC-II/apoC-IV locus (41, 42), and the afore-
mentioned intestinal enhancer element for the apoA-I gene
probably controls intestinal expression of more than one gene
within the apoA-I/apoC-III/apoA-IV locus (34, 35). In each of
these cases, the distant regulatory element occurred in the
setting of a family of related genes that arose by ancient gene
duplication events, and it is not difficult to imagine how these
duplication events might place regulatory elements at a dis-
tance from the genes they control. In contrast, the apoB gene is
not known to have any neighboring family members, and al-
though it is possible that a functionally related gene might be
present in the upstream or downstream sequences, no such
gene has yet been identified. An obvious future goal is to
determine whether related genes are present in the adjacent
sequences and then to determine if those genes are expressed
in the intestine and share regulatory sequences with the apoB
gene. The BAC and P1 bacteriophage clones reported here will
3 For example, an analysis of the promoter for the liver fatty acid-
binding protein gene (Fabpl) in transgenic mice (28) revealed that as
few as 153 bp of proximal promoter sequences were sufficient to confer
expression in both the liver and the intestine.
FIG. 11. ApoB gene expression in a transgenic mouse gener-
ated by co-microinjection of p158 and P1–66. Total liver RNA (5
mg) and total intestinal RNA (25 mg) were used in a RNase protection
assay with a 121-bp human apoB riboprobe. To assess GAPDH expres-
sion, a total of 2 mg of RNA were used for both tissues in an RNase
protection assay with a 316-bp mouse GAPDH riboprobe.
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be very useful for achieving this goal and for further localizing
the sequences controlling intestinal apoB gene expression.
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